Australis Capital Inc.

OTCPK:AUSA.F Stock Report

Market Cap: US$4.5m

Australis Capital Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Australis Capital's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Mar 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Australis Capital makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AUSA.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 229-50240
31 Dec 217-15190
30 Sep 215-30180
30 Jun 212-31150
31 Mar 211-25130
31 Dec 200-39130
30 Sep 200-26110
30 Jun 200-25130
31 Mar 200-23140
31 Dec 190-11120
30 Sep 190-7110
30 Jun 190-470
31 Mar 190-440
31 Dec 180-620
30 Sep 180-500
30 Jun 180-200
31 Mar 180000

Quality Earnings: Insufficient data to determine if AUSA.F has high quality earnings.

Growing Profit Margin: Insufficient data to determine if AUSA.F's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AUSA.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare AUSA.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if AUSA.F's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: AUSA.F has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies